Cargando…

Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson’s Disease

Parkinson’s disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) of the midbrain. Restoration of nigrostriatal dopamine neurons has been proposed as a potential therapeutic strategy for PD. Because currently used PD therapeutics only help relieve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pariyar, Ramesh, Bastola, Tonking, Lee, Dae Ho, Seo, Jungwon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877991/ https://www.ncbi.nlm.nih.gov/pubmed/35216503 http://dx.doi.org/10.3390/ijms23042388

Ejemplares similares

ROS Production and ERK Activity Are Involved in the Effects of d-β-Hydroxybutyrate and Metformin in a Glucose Deficient Condition
por: Lamichhane, Santosh, et al.
Publicado: (2017)

Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience
por: Foley, James E, et al.
Publicado: (2010)

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
por: Russo, Eleonora, et al.
Publicado: (2013)

Cearoin Induces Autophagy, ERK Activation and Apoptosis via ROS Generation in SH-SY5Y Neuroblastoma Cells
por: Bastola, Tonking, et al.
Publicado: (2017)

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure
por: Yin, Meimei, et al.
Publicado: (2011)

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice
por: Berger, Joel P., et al.
Publicado: (2017)

The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice
por: Olivares, Marta, et al.
Publicado: (2018)

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor
por: Wang, Aiying, et al.
Publicado: (2012)

DPP-4 Inhibition and Neuroprotection: Do Mechanisms Matter?
por: Shannon, Richard P.
Publicado: (2013)

Role of A-Kinase Anchoring Protein 1 in Retinal Ganglion Cells: Neurodegeneration and Neuroprotection
por: Bastola, Tonking, et al.
Publicado: (2023)

The Role of DPP4 Activity in Cardiovascular Districts: In Vivo and In Vitro Evidence
por: Pala, L., et al.
Publicado: (2013)

Neuroprotective Role of Atractylenolide-I in an In Vitro and In Vivo Model of Parkinson’s Disease
por: More, Sandeep, et al.
Publicado: (2017)

Clinical Use of DPP-4 Inhibitors
por: Gallwitz, Baptist
Publicado: (2019)

Renoprotective Effects of DPP-4 Inhibitors
por: Kawanami, Daiji, et al.
Publicado: (2021)

Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
por: Foley, James E, et al.
Publicado: (2016)

Sulfuretin Attenuates MPP(+)-Induced Neurotoxicity through Akt/GSK3β and ERK Signaling Pathways
por: Pariyar, Ramesh, et al.
Publicado: (2017)

In Vitro and in Vivo Neuroprotective Effects of Walnut (Juglandis Semen) in Models of Parkinson’s Disease
por: Choi, Jin Gyu, et al.
Publicado: (2016)

Neuroprotective effects of Danshensu on rotenone-induced Parkinson’s disease models in vitro and in vivo
por: Wang, Tian, et al.
Publicado: (2020)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
por: Liu, Jinglong, et al.
Publicado: (2014)

Neuroprotective Effects of Oligosaccharides From Periplaneta Americana on Parkinson’s Disease Models In Vitro and In Vivo
por: Liu, Miao-Miao, et al.
Publicado: (2022)

Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017)

Surfing the Vildagliptin Tsunami
por: Balachandran, Karthik
Publicado: (2020)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo
por: Lee, Chen-Hung, et al.
Publicado: (2019)

Formulation of Lipid-Based Tableted Spray-Congealed Microparticles for Sustained Release of Vildagliptin: In Vitro and In Vivo Studies
por: Al Zahabi, Khaled H., et al.
Publicado: (2021)

Neuroprotective Effect and Mechanism of Thiazolidinedione on Dopaminergic Neurons In Vivo and In Vitro in Parkinson's Disease
por: Wang, Yanqin, et al.
Publicado: (2017)

Acute myocardial infarction associated to DPP-4 inhibitors
por: Nunes, J P L, et al.
Publicado: (2014)

Use of DPP-4 inhibitors in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
por: Das, Sambit, et al.
Publicado: (2021)

Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis
por: Lee, Jung Min, et al.
Publicado: (2019)

Nanofibrous Vildagliptin-Eluting Stents Enhance Re-Endothelialization And Reduce Neointimal Formation In Diabetes: In Vitro And In Vivo [Corrigendum]
Publicado: (2019)

Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin
por: Anno, Takatoshi, et al.
Publicado: (2018)

Drosophila as a Rapid Screening Model to Evaluate the Hypoglycemic Effects of Dipeptidyl Peptidase 4 (DPP4) Inhibitors: High Evolutionary Conservation of DPP4
por: Lagunas-Rangel, Francisco Alejandro, et al.
Publicado: (2023)

The Neuroprotective Effect of Isotetrandrine on Parkinson's Disease via Anti-Inflammation and Antiapoptosis In Vitro and In Vivo
por: Wu, Ching-Hu, et al.
Publicado: (2023)

Effect of Vildagliptin on Hepatic Steatosis
por: Macauley, Mavin, et al.
Publicado: (2015)

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
por: Rhee, Sang Youl, et al.
Publicado: (2021)

Neuroprotective properties of DPP‐4i: A therapeutic target for dementia prevention in elderly diabetic patients?
por: Umemura, Toshitaka, et al.
Publicado: (2023)

DPP4 in Diabetes
por: Röhrborn, Diana, et al.
Publicado: (2015)

Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Andukuri, Radha, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_rttak1ao3n3g6ucm3slqi1ac95